NEW YORK, NY, USA I 03, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of ...

Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

A thermal stability-based proteomic analysis identifies cytoplasmic PEBP1 as a mediator of mitochondrial dysfunction-induced stress response, highlighting its potential role in cellular adaptation ...

Verastem, Inc. (NASDAQ:VSTM – Get Free Report) has been given an average recommendation of “Buy” by the nine analysts that ...

(C) PFS and (D) OS in class 2 versus other MAP2K1 mutant tumors in patients treated with MEK inhibitor–containing treatment regimens ... only when the universally co-occurring MAPK pathway mutational ...

NEW YORK, NY, USA I5, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® ...

under the accelerated approval pathway and granted Priority Review for avutometinib, an oral RAF/MEK clamp, in combination with defactinib, an oral, selective FAK inhibitor, in adult patients with ...

The activation of the RAS/Raf/MEK pathway by polyphenols results in the modulation of neuronal survival ... are powerful antioxidants with anti-inflammatory properties. They act on several signaling ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...